The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2021 | ESAs for the management of lower-risk MDS
Sophie Park, MD, Grenoble Alpes Hospital, Grenoble, France, discusses the use of erythropoietin-stimulating agents (ESAs) for the management of lower-risk myelodysplastic syndromes (MDS), outlining key studies of interest. Prof. Park discusses the EMA approval of epoetin alfa in patients with lower-risk MDS, as well as the variety of ESAs which are currently under investigation and the optimal use of ESAs to maximize response rate. This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.
Disclosures
Sophie Park, MD, has participated in advisory boards with Novartis, Pfizer, Takeda, and BMS/Celgene; has received research grants from Novartis, Pfizer, Takeda, BMS/Celgene and Sandoz; and has received speaker’s honoraria from Novartis, Takeda ad BMS/Celgene.
